Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
72
resultados
Última actualización
18/05/2025 [06:45:00]
Resultados 50 a 72 de 72
Resumen de: US2025138013A1
Disclosed a method of identifying high-risk Acute Myeloid Leukemia patients based upon the expression of a leukemic stem-cell (LSC) associated gene known as Serine Protease Inhibitor Kazal type 2 (SPINK2), the method including: (i) Immunohistochemistry (IHC)-based detection of SPINK2 protein expression, (ii) quantification of SPINK2 expression using a scoring system (range 0-16), whereby high SPINK2 is defined as a score>3 and (iii) utilization of the score to classify patients as high-risk (score>3) or low risk (score 0-3). Additionally, disclosed is a method of treating AML using a small molecule inhibitor (SMI) that selectively targets a domain of SPINK2 protein in leukemic cells highly expressing SPINK2; wherein the SMI reduces SPINK2 protein expression, alters SPINK2 target gene mRNA expression, inhibits SPINK2 function and consequently LSC proliferation/survival. A method of identifying potential candidates for SPINK2-SMI therapy to enhance treatment outcomes, whereby potential candidates refer to patients with high SPINK2 expression, is also disclosed.
Resumen de: AU2023367741A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: WO2025087879A2
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in non-malignant tissues. This obstacle can be minimized by targeting cancer dependencies driven by proteins with tissue- and/or tumor-restricted expression. Here, the inventors show that in acute myeloid leukemia (AML), suppression of the myeloid-restricted PIK3CG/p110γ-PIK3R5/p101 axis blocks AKT signaling, compromises cell fitness, and sensitizes to established AML therapies. Importantly, the inventors find that existing small molecule inhibitors against PIK3CG are insufficient to achieve a sustained longterm anti-leukemic effect. To address this concern, the inventors developed a proteolysis- targeting chimera (PROTAC) heterobifunctional molecule that specifically degrades PIK3CG and potently suppresses AML progression alone and in combination with venetoclax in human AML cell lines, primary AML patient samples, and syngeneic mouse models.
Resumen de: WO2025088065A1
The present invention relates to the field of diagnostics and therapeutics against leukemia. More specifically, it relates to a method for assessing acute myeloid leukemia (AML) in a subject suspected to suffer therefrom comprising the steps of determining in a sample of said subject the amount of at least one biomarker selected from the group consisting of: CLEC7A, CLEC9A, HCST, LST1, LTB, IFITM3, CD74, HLA-DRA, CD164, CD52, CD34, HSPA5, MGST1, CD47, TFPI, IGHM, SELL, CD82, CD69, NDFIP1, RALA, RAB11A, SELENOK, HLA- DRB5, RAMP1, IGLL1, HLA-DQA1, CD96, SLC5A3, VAMPS, CALCRL, LPAR6, NINJ1, CD7, SLC2A5, EREG, FCMR, DLK1, and J AML,, comparing the said amount of the at least one biomarker to a reference, and assessing AML based on the comparison. Yet, the present invention relates to a method for generating a bispecific binding agent and to the use of such bispecific binding agents for treating leukemia, preferably, AML.
Resumen de: WO2025087936A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: WO2025088223A2
The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.
Resumen de: US2024117435A1
Systems and methods for predicting survival outcomes in patients diagnosed with Myelodysplastic Syndrome (MDS) are disclosed. One method may include: receiving DNA sequencing data derived from a methylation assay performed on a biological sample associated with the at least one patient; computing methylation beta-values for one or more CpG-sites identified in the sequencing data; identifying one or more differentially methylated regions (DMRs) based on statistical analysis of the methylation beta-values for the one or more CpG-sites; selecting, via a feature selection process, a subset of the one or more DMRs to utilize as training data; and training, using the training data, the classifier to predict the survival outcome of the at least one patient. Other aspects are described and claimed.
Resumen de: WO2025086418A1
A pharmaceutical composition comprising i) a recombinant fusion protein that comprises a mutated SIRPαD1 and a functional IgG1 heavy chain constant region, and ii) azacitidine, for use in treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof.
Resumen de: EP4545085A1
The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.
Resumen de: AU2023286618A1
The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.
Resumen de: US2025129162A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025129420A1
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Resumen de: US2025127755A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and hi slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Resumen de: US2025127751A1
The disclosure belongs to the technical field of medicine, and specifically discloses a traditional Chinese medicine compound preparation for tumors and application thereof. The traditional Chinese medicine compound preparation includes dimethylarsenic acid, indirubin and cordycepin in a concentration ratio of (1-20):(1-10):(1-40). The traditional Chinese medicine compound preparation of the disclosure can be used for treating kinds of tumors, including leukemia, gastric cancer, lung cancer, glioma, papillary thyroid carcinoma, growth hormone adenoma, pituitary adenoma, myeloma, and other malignant tumors. The traditional Chinese medicine compound preparation has significant treatment effect, high safety, and good development prospects.
Resumen de: US2025129435A1
The present disclosure provides a novel method of diagnosing lymphoma, breast cancer, a lymphoma subtype, or a breast cancer subtype in a patient, and kits for implementing the methods.
Resumen de: US2025127855A1
A method of treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof, comprising the steps of: (a) administering intravenously to the subject for the chronic myelomonocytic leukemia about 2.0 mg/kg body weight per day of a recombinant fusion protein of SEQ ID NO: 1 in the form of a composition comprising a pharmaceutically acceptable excipient and the recombinant fusion protein, (b) about 65 minutes to about 75 minutes after completing the administering of step (a), administering subcutaneously to the subject about 75 mg/m2 of azacitidine, and (c) after steps (a) and (b), repeating step (a) once weekly, and administering subcutaneously to the subject about 75 mg/m2 of azacitidine once daily, wherein on the days that the subject is also having step (a) repeated, the azacitidine is administered about 65 minutes to about 75 minutes after completing the repeated administering of step (a).
Resumen de: WO2025081518A1
Provided is the use of DPP4 as an NK/T cell lymphoma tumor marker, the use of a DPP4 detection reagent in preparing a kit for screening for NK/T cell lymphoma, and the use of a DPP4 inhibitor in preparing a medicine for treating NK/T cell lymphoma.
Resumen de: WO2025085792A1
Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
Resumen de: WO2025085525A2
The present disclosure provides methods for treating acute myelogenous leukemia (AML) in a subject in need thereof comprising administering to the subject an effective amount of an anti-PD-L1 antibody or antigen binding fragment thereof and cytokine induced memory-like natural killer (CIMN) cells.
Resumen de: WO2025085878A1
The present invention relates to compounds of formula (A) as DUX4 inhibitors for the treatment of e.g. neuromuscular disorders, inflammatory disorders, facioscapulohumeral muscular dystrophy, B-cell leukemia, sarcomas, solid cancers, rheumatoid arthritis, axial spondylarthritis, viral infections, mononucleosis, encephalitis, and varicella. Exemplary compounds are e.g.
Resumen de: US2025129431A1
The invention features methods for the identification of genomic aberrations in circulating tumor cells (CTCs) isolated from peripheral blood. In various embodiments of the disclosure, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
Nº publicación: EP4539882A1 23/04/2025
Solicitante:
BEIGENE LTD [KY]
BeiGene, Ltd
Resumen de: CN119365214A
Methods of treating diffuse large B-cell lymphoma (DLBCL) or increasing, enhancing, or stimulating an immune response with antibodies and antigen-binding fragments thereof that specifically bind to TIGIT (T cell immune receptors with Ig and ITIM domains) in combination with an anti-PD1 antibody and/or an anti-CD20 antibody are provided.
BOPI
Sede Electrónica
